Boston, MA, based Investment company North Tide Capital, Llc buys Impax Laboratories, Allergan PLC, Accuray, sells Community Health Systems, Valeant Pharmaceuticals International, Mylan NV, Perrigo Co PLC, Select Medical Holdings during the 3-months ended 2016-12-31, according to the most recent filings of the investment company, North Tide Capital, Llc. As of 2016-12-31, North Tide Capital, Llc owns 14 stocks with a total value of $483 million. These are the details of the buys and sells.
New Purchases: IPXL, AGN, ARAY, Added Positions: MYGN, KND, Reduced Positions: MYL, SEM, SVU, GILD, LPNT, Sold Out: CYH, VRX, PRGO, AFAM, ADUS,
For the details of NORTH TIDE CAPITAL, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=NORTH+TIDE+CAPITAL%2C+LLC
These are the top 5 holdings of NORTH TIDE CAPITAL, LLCSelect Medical Holdings Corp (SEM) – 10,000,000 shares, 27.46% of the total portfolio. Shares reduced by 23.66%SUPERVALU Inc (SVU) – 18,469,921 shares, 17.87% of the total portfolio. Shares reduced by 24.61%Gilead Sciences Inc (GILD) – 500,000 shares, 7.42% of the total portfolio. Shares reduced by 37.5%Kindred Healthcare Inc (KND) – 4,250,000 shares, 6.91% of the total portfolio. Shares added by 6.25%Syneron Medical Ltd (ELOS) – 3,500,000 shares, 6.09% of the total portfolio. New Purchase: Impax Laboratories Inc (IPXL)
North Tide Capital, Llc initiated holdings in Impax Laboratories Inc. The purchase prices were between $12.75 and $24.23, with an estimated average price of $17.1. The stock is now traded at around $9.15. The impact to the portfolio due to this purchase was 5.49%. The holdings were 2,000,000 shares as of 2016-12-31.
Top Medical Stocks To Buy For 2018: Biotricity (BTCY)
Advisors’ Opinion:
- [By Robert J. Smith]
Biotricity (OTCBB: BTCY) is a comer in the rapidly growing medical device market and is a small cap to take notice of. Driving this lucrative market are; IoT-driven device connectivity, governmental pressure to cut healthcare costs, escalating hospital costs, a need to reduce hospital readmission rates, an aging population, and a high rate of people with chronic disease. The largest factor driving this market is the rapidly growing rate of those afflicted with chronic disease.
- [By Peter Graham]
Sandhill.com recently interviewed the chairman, CEO and founder Waqaas Al-Siddiq small cap wearables stock Biotricity (OTCQB: BTCY) about how wearables benefit patients, integrate into healthcare systems and improve treatment compliance as well as how the cloud and the Internet of Things impact the medical wearables space. biotricitys is a medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricitys R&D focuses on the preventative healthcare market, with a vision of putting health management into the hands of the individual by supporting the self-management of critical and chronic conditions.
- [By Matthew Briar]
Ever heard the term ‘mHealth’? Or, maybe you’ve heard it by the full-length (and less hip) characterization mobile health. Regardless of what you call it, it’s the same … it’s the Q&D way to describe the new era of healthcare and medical equipment that operates outside of a hospital or clinic, and doesn’t require any wires to function. It’s the new way of taking care of patients, and more important, it’s a huge market. The mHealth market is projected to grow from $13.6 billion in 2015 to $49.1 billion by 2020, as the premise and technology hits a critical mass.
It’s an undertow – a paradigm shift – that favors lots of small cap stocks, but perhaps none as much as Biotricity Inc (OTCMKTS:BTCY).
Biotricity isn’t a household name. It may be soon, however. It’s the developer of two different but related wearable, 24/7 heart monitoring technologies. The device called bioflux is for use by caregivers in a clinical setting, remotely transmitting detailed information about the heart’s functioning which can then be analyzed by caregivers. The device known as biolife serves individuals outside of a clinical setting, largely doing the same chore. The advantage of the technology is mobility, without sacrificing accuracy.
The device furthest along the development path is bioflux. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device.
The two devices utilize the same basic technology, but are clearly addressing different markets.
It must also be noted that the ECG monitoring software found in a bioflux has been approved by the FDA in the past and is already rather standard technology for ECG monitoring equipment in hospitals and
Top Medical Stocks To Buy For 2018: Merrimack Pharmaceuticals, Inc.(MACK)
Advisors’ Opinion:
- [By Lisa Levin] Gainers
Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than - [By Paul Ausick]
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) dropped nearly 11% on Tuesday to post a new 52-week low of $3.30 after closing at $3.67 on Monday. Volume was more than 3 times the daily average of about 3.7 million shares. The stock’s 52-week high is $9.02 The company said Tuesday that it has sold some of its cancer drugs to Ipsen for $1 billion.
- [By Lisa Levin]
Check out these big penny stock gainers and losers
Losers
Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market
Top Medical Stocks To Buy For 2018: L.B. Foster Company(FSTR)
Advisors’ Opinion:
- [By Lee Jackson]
The L.B. Foster Co. (NASDAQ: FSTR) had one of itsdirectors adding to a position last week. Legion Partners bought 72,301 shares of the transportation and energy infrastructure company at prices between $12.27 and $13.07. The total for the purchase came in right at $1 million. The shares closed Friday at $13.30, in a 52-week range of$9.25 to $20.77. The consensus price target is $15.00.
- [By Lisa Levin]
Friday afternoon, the basic materials sector proved to be a source of strength for the market. Leading the sector was strength from Intrepid Potash, Inc. (NYSE: IPI) and L.B. Foster Co (NASDAQ: FSTR).
- [By Lisa Levin]
Wednesday afternoon, basic materials shares gained by 1.74 percent. Meanwhile, top gainers in the sector included Intrepid Potash, Inc. (NYSE: IPI), and L.B. Foster Co (NASDAQ: FSTR).
Top Medical Stocks To Buy For 2018: American Express Company(AXP)
Advisors’ Opinion:
- [By Paul Ausick]
American Express Co. (NYSE: AXP) traded up 0.57% at $88.70. The stock’s 52-week range is $59.50 to $89.38. Volume was about half the daily average of around 3.2 million. The company had no specific news Tuesday.
- [By Cooper Creagan]
Since then, the money spent using prepaid cards has nearly doubled, as big players like Wal-Mart Stores Inc. (NYSE: WMT) and American Express Co. (NYSE: AXP) have entered the game with the prepaid Bluebird card.
- [By Garrett Baldwin]
The Ripple coin topped $0.23 after a 10% surge during Thursday trading. The price surged after credit card giant American Express Co. (NYSE: AXP) announced it has established a payments corridor between the United States and the United Kingdom using Ripple’s technology.
- [By Paul Ausick]
American Express Co. (NYSE: AXP) traded up 1.41% at $99.36. The stock’s 52-week range is $75.51 to $102.39. Volume was about 10% above the daily average of around 3.4 million shares. The company had no news Wednesday.
- [By Chris Lange]
American Express Co. (NYSE: AXP) will share its latest quarterly earnings on Wednesday. The consensus estimates call for $1.48 in EPS and $8.29 billion in revenue. Shares ended last week at $92.86, in a 52-week range of $59.78 to $92.92. The consensus analyst target is $89.91.
- [By Paul Ausick]
American Express Co. (NYSE: AXP) traded down 0.64% at $73.89. The stock’s 52-week range is $50.27 to $75.74. Volume was less than half the daily average of around 4.7 million shares. The company had no specific news.
